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DOI 10.1016/j.ccr.2011.08.007SUMMARYWe investigated the potential of in-depth quantitative proteomics to reveal plasma protein signatures that
reflect lung tumor biology. We compared plasma protein profiles of four mouse models of lung cancer
with profiles of models of pancreatic, ovarian, colon, prostate, and breast cancer and two models of inflam-
mation. A protein signature for Titf1/Nkx2-1, a known lineage-survival oncogene in lung cancer, was found in
plasmas of mouse models of lung adenocarcinoma. An EGFR signature was found in plasma of an EGFR
mutant model, and a distinct plasma signature related to neuroendocrine development was uncovered in
the small-cell lung cancer model. We demonstrate relevance to human lung cancer of the protein signatures
identified on the basis of mouse models.INTRODUCTION
Mouse models of cancer, in particular genetically engineered
mousemodels (GEMs) in which genetic alterations in oncogenes
and tumor suppressors known to be mutated in human cancer
are introduced, recapitulate many features of the human disease
on a more uniform genetic background. For example, mouse
models have been used to study the role of mutant KRAS and
EGFR in the genesis of lung adenocarcinomas. As in humans
with EGFR mutant lung cancer, mice with this disease respondSignificance
We have applied a comparative strategy of mousemodels of ca
lineages of lung cancer, or that reflect pathways driving tumor
cancer were identified in plasmas from lung cancer models com
inflammation. We also obtained evidence for concordant findin
from subjectswith lung cancer at the time of diagnosis aswell a
nosis supporting the merits of comparative profiling of mouse
relevant to humans.
Canto treatment with a tyrosine kinase inhibitor (Politi et al., 2006).
Similarly, the deletion ofRb and Trp53, genes that are inactivated
in the vast proportion of human small-cell lung cancers (SCLCs),
in the murine lung leads to the development of tumors that reca-
pitulate the features of this histological subtype (Meuwissen
et al., 2003; Schaffer et al., 2010).
To determine whether we could identify plasma protein signa-
tures that are common to lung adenocarcinomas or that reflect
pathways driving tumor development, we examined the plasma
proteomes of several mouse lung tumor models, in comparisonncer to uncover protein signatures in plasma that reflect cell
development. Proteins not previously associated with lung
pared with plasmas from other cancer models or models of
gs in human lung cancer cell lines and in plasmas collected
s in sera collected from asymptomatic subjects prior to diag-
models of cancer for the discovery of proteomic signatures
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Lung Cancer Protein Signatures in Mouse Plasmawith the plasma proteomes of models of other tumor types. We
also extended these findings to human patients with lung cancer.
RESULTS
A Plasma Protein Signature for Lung Adenocarcinoma
Plasma proteins from tumor-bearing mice and age-matched
littermate controls were subjected to quantitative profiling by
mass spectrometry as previously described (Faca et al., 2008)
(see Table S1, which is available with this article online). Plasma
was collected from three well-characterized models of lung
adenocarcinoma: TetO-EGFRL858R/CCSP-rtTA (Lung-EGFR)
(Politi et al., 2006), TetO-Kras4bG12D/CCSP-rtTA (Lung-Kras)
(Fisher et al., 2001), and urethane treated (Lung-Urethane) (Horio
et al., 1996). Plasma was collected 5–6 weeks (Lung-EGFR) and
5–6 months (Lung-Kras) after starting doxycycline treatment,
representing early and intermediate stages of tumorigenesis,
respectively (Fisher et al., 2001; Politi et al., 2006). For the
urethane mouse model, plasma was collected at 38–42 weeks
of age from mice bearing multiple adenomas and adenocarci-
nomas that harbor frequent Kras and Trp53 mutation (Horio
et al., 1996). Plasma was also collected from a mouse model
of small-cell lung cancer (Lung-SCLC) (Meuwissen et al.,
2003), aged for 6–9 months following AdCre infection. In the
SCLC model, AdCre-infected Trp53lox/lox; Rblox/lox mice develop
neuroendocrine tumors that resemble SCLCs histologically
(Meuwissen et al., 2003). The resulting proteomic data from
tumor-bearing mice and matched controls for all four lung
cancer models were compared with corresponding data from
other models for which plasma proteome data was available to
delineate lung cancer signatures. They consisted of two mouse
models of breast cancer (MMTV-rtTA/TetO-NeuNT; (Breast-
HER2) [Moody et al., 2002; Pitteri et al., 2011] and Tg(MMTV-
PyMT)634Mul; (Breast-PyMT 0.5 cm) and (Breast-PyMT 1.0 cm),
representing early and late stages of tumor development,
respectively [Pitteri et al., 2008]), two prostate cancer models
(Ptenpc/ mice bearing nonmetastatic tumors compared
with Ptenpc/;Smad4pc/ mice bearing metastatic tumors;
(Prostate-Strain Comparison) [Ding et al., 2011]), and one
model each of colon (ApcD580/+; (Colon-Apc) [Hung et al.,
2009)], ovarian (LSL-KrasG12D/+;PtenloxP/loxP; (Ovary-Kras/Pten)
[Dinulescu et al., 2005; Pitteri et al., 2009)] and pancreatic
ductal adenocarcinoma (PDAC) (Pdx1-Cre;LSL-KrasG12D;Ink4a/
Arflox/lox; (Pancreas-PanIN [pancreatic intraepithelial neoplasia])
and (Pancreas-PDAC), representing early and late stage of tumor
development, respectively [Faca et al., 2008]). Additionally, the
plasma proteomes of two mouse models of inflammatory
disease were also assessed to ascertain whether alterations
observed in the plasma of the tumor models were related
to general inflammatory processes. These included a mouse
model bearing necrotic granulomatous tissue induced by carra-
geenan-sponge implantation (Confounder-Acute Inflammation)
and a model consisting of type II collagen-induced arthritis
(Confounder-Chronic Inflammation) (Kelly-Spratt et al., 2011).
For each model, we quantified the relative concentrations of
proteins in case and control plasmas by differential cysteine
alkylation in intact proteins using isotopically labeled acrylamide
(Faca et al., 2006). We identified protein products from 5361
unique genes with <5% false discovery rate from 13 million290 Cancer Cell 20, 289–299, September 13, 2011 ª2011 Elsevier Inspectra in 14 proteomic profiling experiments with plasmas
from individual mouse models (Table S2). Case:control protein
concentration ratios were calculated according to identification
of cysteine-containing peptides from the protein products of
2261 unique genes (Table S3).
Unsupervised hierarchical clustering analysis of quantified
plasma proteins revealed clustering of models by organ type,
with all four lung cancer models clustering together as well as
the two breast cancer models, suggestive of organ-type specific
plasma protein signatures (Figure 1). To further explore protein
signatures associated specifically with lung adenocarcinoma,
the plasma proteome data was analyzed for proteins that were
significantly elevated (case:control ratio > 1.25; p < 0.05, t test)
in mice bearing lung adenocarcinoma tumors or only identified
in tumor bearing mice from at least two of the three lung adeno-
carcinoma models, but not in other mouse models. This filtering
strategy yielded 13 proteins (Table 1; Lung adeno subgroup in
Table S4) including the known lung surfactant proteins (Sftpb
and Sftpd) (Pe´rez-Gil, 2008). Three additional proteins (Igsf4a,
Ppbp, and Prtg) exhibited increased levels in mice bearing
adenocarcinomas as well as in mice bearing SCLC tumors but
not in nonlung tumor models, thus representing proteins more
broadly associated with lung cancer (Table 1; Lung cancer
subgroup in Table S4). Independent evidence of PPBP as
a lung cancer marker has been reported on the basis of human
studies (Yee et al., 2009). Proteins with significantly decreased
concentrations (case:control ratio < 0.8; p < 0.05, t test) were
also identified in the lung adenocarcinoma models (Table S4).
Of potential broader cancer relevance, we identified 16 addi-
tional proteins that were altered across multiple cancer models,
but not in confounder mouse models, and thus represent poten-
tial broad epithelial tumor signatures (Common subgroup in
Table S4). One such protein is Wfdc2, which has been associ-
ated with ovarian cancer (Hellstro¨m et al., 2003). Of interest,
WFDC2 was found to be expressed in human lung tumor tissue,
although not previously known to be elevated in lung cancer
plasmas (Bingle et al., 2006; Galgano et al., 2006). Another
subset of seven proteins was elevated in plasmas from both
cancer models and the inflammatory models (Inflammation
subgroup in Table S4). This subset included platelet-derived
chemokine Cxcl4/Pf4, a cleaved form of which has been recently
reported as associated with breast ductal carcinoma in situ (Sol-
assol et al., 2010) and Angptl3, which has not been previously
associated with lung cancer. Angptl3 plays a role in lipid metab-
olism (Koishi et al., 2002), induces angiogenesis (Camenisch
et al., 2002), and has been found to be associated with the
sera of ovarian cancer (Lin et al., 2009).
Next, we examined whether proteins with increased levels in
plasmas from lung tumor-bearing mice are expressed in lung
cancer cells and may be released into the extracellular space
(Fac¸a and Hanash, 2009). To this end, the proteomes of 21
human lung adenocarcinoma cell lines were analyzed by mass
spectrometry to identify proteins in whole cell extracts, and
proteins specifically on the cell surface or released into the
medium. These comparisons revealed that 25 of 39 proteins
found at increased levels in plasmas frommice with lung adeno-
carcinoma (Table S5) were identified in conditioned media, and
an overlapping set of 26 proteins were found in the cell surface
compartment of lung adenocarcinoma cell lines. Twenty one ofc.
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Figure 1. Clustering of Plasma Proteome Profiles of Mouse Models of Lung Cancer
Unsupervised hierarchical clustering was performed for proteins quantified in plasmas frommousemodels based on differential cysteine labeling. Plasma protein
profiles of all four lung cancer mouse models yielded a distinct cluster. A close-up view of distinct clusters of proteins with elevated and decreased levels in
plasma from lung cancer mouse models is shown in the lower panels.
Cancer Cell
Lung Cancer Protein Signatures in Mouse Plasmathe 39 proteins were enriched more than 5-fold in the condi-
tionedmedia compared to their abundance in whole cell extracts
(Table 1 and Table S5). Together, these profile comparisons
suggest that lung cancer cells are a likely contributing source
for the increased levels of these proteins in plasmas from mice
with lung adenocarcinomas.
A Titf1/Nkx2-1 Signature in the Plasma of Mice
with Lung Adenocarcinomas
Sftpb and Sftpd, which were elevated in lung adenocarcinoma
plasma profiles are secreted by alveolar cells and play an essen-
tial role in lung function by reducing surface tension (Pe´rez-Gil,
2008). These proteins are encoded by genes that are known
targets of Titf1/Nkx2-1, a master transcription factor of periph-
eral airway cells and a known lineage-specific determinant of
survival in lung cancer cells (Tanaka et al., 2007; Weir et al.,
2007). Expression of Titf1/Nkx2-1 protein in lung tumors was
confirmed by immunohistochemistry (Figure 2A). On this basis,
we speculated that additional targets of Titf1/Nkx2-1 might be
represented at increased levels in the plasma proteomes of
the lung adenocarcinoma models. To further delineate a Titf1/
Nkx2-1 plasma proteome signature, we examined mRNAmicro-
array data from a set of 111 human NSCLC tumors, including
both adenocarcinomas and squamous cell carcinomas (acces-
sion number, GSE3141; Bild et al., 2006). Orthologous genes
encoding four proteins with increased levels in the murine lung
adenocarcinoma plasmas (SFTPB, SFTPD, NPC2, andWFDC2)Canexhibited a strong positive correlation with TITF1/NKX2-1mRNA
levels (Spearman correlation coefficient > 0.6; p < 0.00001)
(Table S6). NPC2, a cholesterol transfer protein implicated in
Niemann-Pick disease (Vanier and Millat, 2004), was not previ-
ously known to be elevated in lung cancer plasma. Expression
of the NPC2 gene showed a strong correlation with TITF1/
NKX2-1mRNA across the set of human lung tumors (Spearman
correlation coefficient = 0.64) providing supportive evidence for
NPC2 as a potential target of this transcription factor in lung
cancer cells. Immunohistochemical staining for Npc2 and Sftpb
in mouse lung cancer tissue (Figure 2A) indicated that these
proteins as well as Titf1/Nkx2-1 are coexpressed in lung
tumor cells. Additional data associating NPC2 with lung cancer
included identification of NPC2 in media of all 21 lung adenocar-
cinoma cell lines (Table S5) and occurrence of NPC2 among 300
proteins found in pleural effusions associated with lung cancer
(Pernemalm et al., 2009).
To further determine the role of Titf1/Nkx2-1 in the expression
of genes encoding proteins found at elevated levels in plasmas
from lung cancer models, we examined the effects of inhibiting
Titf1/Nkx2-1 in two lung adenocarcinoma cell lines with high
expression of TITF1/NKX2-1: HCC4019 (KRAS mutant) and
H3255 (EGFR L858R mutant) (Figure 2B). TITF1/NKX2-1 knock-
down experiments were performed twice with each cell line.
Gene expression analysis yielded a total of 964 genes with
average case:control RNA ratios of less than 0.75 in one or
both cell lines following knockdown. Plasma data were availablecer Cell 20, 289–299, September 13, 2011 ª2011 Elsevier Inc. 291
Table 1. Plasma Proteins with Significantly Elevated Levels in Tumor-Bearing Mice from the Lung Adenocarcinoma Models
Gene
Lung Mouse Models Cell Lines
EGFR Kras Urethane SCLC Total Cell Extract Cell Surface Media
Sftpb 4.83 3.41 1.99 — 0 1 2
Morc3 * 10 10 — 0 0 0
Fgfr2 9.8 * — — 2 1 0
Adam10 7.85 1.5 — — 3 12 11
Man2b2 4.22 1.46 — — 1 0 7
Tfpi2 10 * — — 5 5 8
Son * 10 — — 1 1 6
Eif2ak3 * 9.03 — — 1 0 0
Hamp2 * 3.07 — — NA NA NA
Ncan * 1.45 — — 2 1 0
Sftpd 10 — 10 — 2 1 3
Mocs1 1.71 — 1.3 — 0 0 1
Nup188 — * 10 — 0 1 1
Igsf4a 3.55 1.48 1.55 3.32 0 0 0
Ppbp 1.63 1.7 5.12 1.39 0 0 0
Prtg 10 10 — 10 0 0 0
Numbers for each mouse model indicate the case:control ratio based on the identification of peptides containing cysteine residues labeled with heavy
and light acrylamide isotopes. Dashes (—) indicate that the quantitative ratio was not calculated. Asterisks (*) indicate proteins that were only identified
in plasma from tumor-bearing mice. Thirteen proteins were significantly elevated (case:control ratio > 1.25; p < 0.05, t test) in mice bearing lung adeno-
carcinoma tumors or only identified in tumor bearing mice from at least two of the three lung adenocarcinoma models, but not in any other mouse
models. Three proteins (Igsf4a, Ppbp, and Prtg) were increased in mice bearing adenocarcinomas and SCLC tumors but not in the other models.
The numbers in the columns for cell lines indicate the number of cell lines in which a protein was identified in any of the whole cell extract, the cell
surface, or the conditioned media. The entire dataset is available in Table S4 and Table S5.
Cancer Cell
Lung Cancer Protein Signatures in Mouse Plasmafor protein products of 34 genes among the 964 potential TITF1/
NKX2-1-regulated genes, including Sftpa1, Sftpb, Sftpd, and
Npc2 (Table S7). The average plasma ratios of these proteins
in tumor-bearing mice from lung adenocarcinoma mouse
models relative to controls were significantly higher than plasma
ratios for other mouse models (mean ± standard deviation:
2.28 ± 0.07 versus 1.20 ± 0.37; p = 0.0005, t test) (Figure 2C),
providing further supporting evidence for a Titf1/Nkx2-1 regu-
lated protein set in plasmas of mice with lung adenocarcinoma.
We also observed a strong correlation between expression ofBA
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tumors according to expression array analysis (Table S7), further
supporting their regulation by TITF1/NKX2-1 transcription factor.
Dominant Networks in Plasmas from Mice
with Genetically Engineered Lung Cancers
We searched for dominant networks among proteins with signif-
icantly altered levels in plasmas from genetically engineered
lung cancer mouse models based on Ingenuity Pathway
Analysis (http://www.ingenuity.com/). We observed 21, 15, and9
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Figure 2. A Titf1/Nkx2-1 Signature in the
Plasma of Lung Adenocarcinoma Tumor-
Bearing Mice
(A) Immunohistochemical staining of mouse lung
cancer tissue for Titf1, Sftpb, and Npc2 in the
EGFR and Kras lung cancer models. Scale bars
represent 20 mm.
(B) Knockdown of TITF1 with siRNA in two lung
cancer cell lines, HCC4019 (KRAS mutant) and
H3255 (EGFR mutant), was verified by western
blotting. GAPDH served as a loading control.
(C) The average ratios of potential Titf1-regulated
proteins in plasma from mice with disease relative
to controls for the different mouse models. Bars
indicate mean and standard deviation of ratios for
proteins quantified in each mouse model. p value
was calculated by t test.
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Figure 3. An Egfr Protein Network in the Plasma of Mice with Tumors Induced by Mutant EGFR
(A) A protein network involving EGFR was found in the plasma from mice with EGFR mutant lung adenocarcinoma. Proteins highlighted in red were significantly
elevated or uniquely identified, and proteins highlighted in green were significantly decreased in plasma from tumor-bearing mice. Solid lines and dashed lines
indicate direct and indirect interactions, respectively.
(B) Normalized spectral counts, indicative of protein abundance, of CDH1 in conditioned media and cell surface compartments of 10 EGFR mutant lung cancer
cell lines compared with 11 KRAS mutant lung cancer cell lines. Columns indicate average and error bars indicate standard deviation.
(C) Cd44 peptides identified in lung cancer mouse models. Black bars indicate sequence location of peptides.
(D) Alternative splicing variants ofCD44 in 21 lung adenocarcinoma cell lines. The locations of the common and the representative variant form ofCD44 observed
in EGFR mutant cell lines are indicated with an asterisk and an arrowhead, respectively. The no template control is indicated as NTC.
(E) Ratios of plasma Egfr levels in (1) lung adenocarcinoma tumor-bearingmice compared to controls, (2) inmice following injection of IL-6 relative to baseline, and
(3) in tumor-bearing mice compared to controls for other mouse models investigated. Two replicates of IL-6 injection experiment (#1 and #2) were independently
analyzed by mass spectrometry. The error bar indicates standard deviation.
(F) Return toward baseline following tumor regression of proteins with altered levels in tumor-bearing mice in the EGFR mutant mouse model. p value was
calculated by paired t test.
Cancer Cell
Lung Cancer Protein Signatures in Mouse Plasma17 networks with statistical scores of more than 10 (score =
log10 [p value] based on the right-tailed Fisher’s exact test) in
EGFR, Kras, and SCLC lung cancermousemodels, respectively.
Protein networks involving TGFb were observed in plasma with
high significance among all lung cancer models (network #4 in
the Lung-EGFR model; #5 in the Lung-Kras model; #2 in the
Lung-SCLCmodel) (Table S8). NFkBwas also found in networks
with high significance among all three models. Networks
involving TGFb or NFkB may reflect a host response to the
tumors based on the associated proteins and/or may reflect
functional roles for these pathways in lung tumor formation.CanNFkB signaling has been shown to be required for mouse lung
adenocarcinoma development (Meylan et al., 2009). Interest-
ingly a network involving Egfr was the most statistically signifi-
cant network (score = 38) in the EGFR mutant mouse model
(Figure 3A), whereas it was observed as network #8 (score =
23) in the Kras mutant mouse model. A network involving Egfr
was also highly significant (score = 41) in the SCLC model (Fig-
ure S1A). Messenger RNA expression of Egfr was found to be
elevated in tumor tissue compared to normal lung tissue in this
SCLC model (accession number, GSE18534; Schaffer et al.,
2010). Thus, this SCLC model may recapitulate EGFR-positivecer Cell 20, 289–299, September 13, 2011 ª2011 Elsevier Inc. 293
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Figure 4. A Distinct Neuroendocrine Signature in Plasma of Mice
with SCLC
(A) Venn diagrams of elevated (case:control ratio > 1.25; p < 0.05, t test)
proteins that were in common or unique to the EGFR, Kras, and SCLC mouse
models.
(B) Plasma protein case:control ratios (>1.5) and corresponding gene
expression ratios (>1.25) in tumor tissue from the SCLC mouse model
compared to controls.
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Lung Cancer Protein Signatures in Mouse Plasmahuman SCLC, which occurs in 40% of SCLC (Schmid et al.,
2010). The plasma Egfr network observed in the EGFR mutant
mouse model includes proteins that bind directly with EGFR
(Met, Cd44, Cdh1, Ndn, Sh3bgrl, and Rin1) and proteins that
interact indirectly with EGFR (Adam10 and Trak2/Als2cr3).
Among proteins that bind directly with EGFR, Met, Cdh1, and
Sh3bgrl were predominantly elevated in tumor bearing mice
from the EGFR mutant mouse model (Table S3). Moreover
CDH1 occurred at higher levels in EGFR mutant lung adenocar-
cinoma cell lines than in KRAS mutant lung adenocarcinoma cell
lines (Figure 3B). Interestingly, one form of Cd44 (IPI00265503)
was only identified in the EGFR mutant mouse model. This
form represents a longer Cd44 variant (Figure 3C). Proteomic
analysis of 21 lung adenocarcinoma cell lines revealed that
peptides encoding the CD44 variant region were identified in 4
of 10 EGFR mutant cell lines, but none of 11 KRAS mutant cell
lines (p = 0.0351, Fisher’s exact test) (Figure S1B). Concordantly,
alternative splicing RNA variants of CD44 were associated with
EGFR mutant compared with KRAS mutant lung adenocarci-
noma cell lines (p = 0.0237, Fisher’s exact test) (Figure 3D).
Interestingly, although proteins that form an Egfr network were
observed in plasma from tumor-bearingmice in the EGFRmouse
model, levels of endogenous mouse Egfr in plasma from tumor-
bearing mice in this model as well as the two other lung adeno-
carcinoma models were reduced (Table S4) compared to other
models (p = 0.0018, t test) (Figure 3E). We hypothesized that
soluble factors produced by lung tumors and/or through a host
response may induce down-regulation of circulating levels of
soluble Egfr, a major source of which in the mouse is the liver.
Indeed, EgfrmRNA expression levels in liver from tumor-bearing
EGFR mutant mouse model were decreased compared to
controls (data not shown). In view of reports that IL-6 is induced
at high levels in some primary human lung adenocarcinomas
(Gao et al., 2007) and that its levels are increased in the plasma
of patients with lung cancer (De Vita et al., 1998; Kaminska et al.,
2006), although IL-6 was not detected by mass spectrometry in
plasmas from mouse models possibly because of assay sensi-
tivity, we examined the systemic effect of IL-6 administration
on plasma levels of soluble Egfr. A similar reduction in plasma
Egfr levels was observed with IL-6 treatment as in plasmas
from lung tumor-bearing mice (Figure 3E), consistent with our
hypothesis that soluble factors may induce down-regulation of
Egfr in host tissues with lung tumor development.
Erlotinib-Treatment of Mice with EGFR Mutant
Lung Tumors Restores Levels of Plasma Proteins
toward Baseline
To assess protein levels in the context of treatment-induced
changes in tumor volume, we compared plasma protein profiles
of tumor-bearing mice carrying the EGFRL858R transgene before
and after erlotinib treatment (Lung-Regression model; Politi
et al., 2006). CCSP-rtTA; EGFRL858R mice were fed doxycycline
for 5–6 weeks to induce tumors and were subsequently treated
with 25 mg/kg/day of erlotinib for two weeks, after which plasma
was collected. Plasma samples from mice in which tumor
regression was documented were analyzed and compared to
their control erlotinib-treated littermates. In total, levels of 91 of
164 proteins that were either elevated or decreased in plasmas
from tumor-bearingmice in the EGFRmodel and that were quan-294 Cancer Cell 20, 289–299, September 13, 2011 ª2011 Elsevier Intified in the regression model, returned toward baseline (Fig-
ure 3F and Table S9). Thus, using this approach, we have iden-
tified proteins (e.g., Npc2 and Adam10) whose abundance
reflects tumor progression and regression status in the EGFR
model.Plasma from SCLC Tumor-Bearing Mice Exhibits
a Distinct Signature
SCLC exhibits distinct molecular characteristics compared
to lung adenocarcinoma. Analysis of the plasma proteome of
the SCLC mouse model yielded 116 proteins that were signifi-
cantly elevated (case:control ratio > 1.25; p < 0.05, t test) in
tumor-bearing mice but not in either the EGFR or Kras model
(Figure 4A and Table S10). Ingenuity Pathway Analysis of these
116 proteins revealed that 33 (28.4%) proteins were associatedc.
Table 2. Demographics of Subjects and Histology of Tumors
Newly Diagnosed Set Prediagnostic Set
NSCLC SCLC Control NSCLC Control
No. % No. % No. % No. % No. %
Total 28 100 10 100 39 100 26 100 26 100
Age (years)
Mean 63.3 64.1 61.7 65.2 64.5
SD 10.7 7.9 9.6 6.4 6.1
Sex
Female 13 46 8 80 22 56 6 23 6 23
Male 15 54 2 20 17 44 20 77 20 77
Histology
Adenocarcinoma 17 61 — — 11 42 —
Squamous 11 39 — — 10 38 —
Other NSCLC — — — 5 19 —
SCLC — 10 100 — — —
Time span to diagnosis (months)
Mean 6.2
Range 0–11
Cancer Cell
Lung Cancer Protein Signatures in Mouse Plasmawith Neurological Disease or Nervous System Development and
Function pathways (Table S10), pointing to a neural signature in
the plasma protein profile of the SCLC mouse model, consistent
with the neuroendocrine feature of SCLC. A significant network
in the SCLC model consisted of proteins in the proteasome-
ubiquitin pathway (Figure S1A and Table S8). Anti-apoptotic
Bcl-2 overexpression, induced by proteasome-mediated NFkB
activation, is observed in up to 90% of SCLCs, and inhibition
of the proteasome pathway represents a potential therapeutic
modality (Ben-Ezra et al., 1994; Lara et al., 2006),. A subset of
the proteins with increased plasma levels (case:control ratios >
1.5) in tumor-bearing mice in the SCLC model also exhibited
increased expression (case:control ratio > 1.25) of their corre-
sponding genes in tumor tissue compared to normal lung tissue
from the SCLC mouse model (accession number, GSE18534;
(Schaffer et al., 2010) (Figure 4B), including Ncam1/Cd56, which
has been previously associated with SCLC (Ledermann et al.,
1994; Vangsted et al., 1994).
Concordance of Plasma Protein Changes Between
Murine and Human Lung Cancer
To determine the potential relevance to human lung cancer of
findings from mouse models, we performed assays in human
blood samples of a set of proteins consisting of SFTPB, WFDC2,
ANGPTL3, and EGFR for NSCLC and ROBO1 for SCLC, for
which ELISAs were available. One source of human plasmas
was from newly diagnosed smokers with operable NSCLC
(n = 28) and control subjects matched for age, sex, smoking
status, ethnicity, and plasma collection protocol (n = 39) (newly
diagnosed set). A second set consisted of sera collected from
subjects 0–11 months before they were diagnosed with NSCLC
(n = 26) and matched control subjects who remained cancer
free over a 4-year follow-up period (n = 26) (prediagnostic set)
that were part of the Carotene and Retinol Efficacy Trial cohort
study (Goodman et al., 2004). Demographics of subjects in these
two sample sets are summarized in Table 2. For the group ofCannewly diagnosed subjects, EGFR levels were decreased in
subjects with lung cancer, and SFTPB, WFDC2, and ANGPTL3
levels were elevated with statistical significance, concordant
withour findings inmousemodels (p<0.05 in t test orMann-Whit-
ney test) (Figure 5A). A receiver operating characteristic (ROC)
analysis of the combined panel of EGFR, SFTPB, WFDC2, and
ANGPTL3 using a linear combination rule yielded an AUC of
0.882 for the newly diagnosed set (Figure 5B). To further assess
the potential contribution of the marker panel to early detection
of lung cancer, we compared performance of the marker panel
in the prediagnostic sample set with the performance of a
previously validated panel (Qiu et al., 2008) consisting of auto-
antibodies to ANXA1, YWHAQ, and LAMR1 (autoantibody panel)
in the same sample set (Figures 5C and 5D). For the group of
subjects with sera collected before a diagnosis of NSCLC, an
AUC of 0.808 was observed for the EGFR, SFTPB, WFDC2,
and ANGPTL3 panel compared with 0.828 for the autoantibody
panel and an AUC of 0.898 for the two panels combined.
Given the finding of substantially increased levels of the neural
protein Robo1 in tumor-bearing mouse plasma from the SCLC
mouse model (Figure 4B), we examined the levels of this protein
in human plasmas. An ELISA assay targeting the ectodomain of
ROBO1 yielded significantly increased levels in plasma from
patients with SCLC in comparison with levels in plasmas from
control subjects without cancer (n = 10 and 39, respectively; Fig-
ure 5E), On the other hand, the levels of ROBO1 were not signif-
icantly elevated in plasmas from subjects with NSCLC (n = 28) in
the newly diagnosed set (data not shown), suggesting that
ROBO1 is a SCLC-specific biomarker, concordant with the find-
ings from the SCLC mouse model.
DISCUSSION
Genetically engineered mouse models of human cancer have
generated remarkably concordant histopathology, genetic pro-
files, and response to therapeutics when compared to theircer Cell 20, 289–299, September 13, 2011 ª2011 Elsevier Inc. 295
CA
Assay Normal Cancer T-test Mann Whitney test
EGFR 1.00 ± 0.048 0.87 ± 0.051 0.0635 0.0287
SFTPB 1.00 ± 0.110 1.57 ± 0.144 0.0027 0.0031
WFDC2 1.00 ± 0.120 1.54 ± 0.237 0.0489 0.1049
ANGPTL3 1.00 ± 0.075 1.17 ± 0.080 0.1192 0.1561
Pre-diagnostic set
Assay Normal Cancer T-test Mann Whitney test
EGFR 1.00 ± 0.067 0.77 ± 0.041 0.0094 0.004
SFTPB 1.00 ± 0.135 1.43 ± 0.205 0.0708 0.0332
WFDC2 1.00 ± 0.233 4.70 ± 1.145 0.0005 < 0.0001
ANGPTL3 1.00 ± 0.073 1.53 ± 0.205 0.008 0.0038
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Figure 5. Concordance of Plasma Protein Changes Between Murine and Human NSCLC
(A–D) Plasma levels of EGFR, SFTPB, WFDC2, and ANGPTL3 were determined by ELISA in samples from newly diagnosed subjects with NSCLC (n = 28) relative
to matched control subjects (n = 39) (newly diagnosed set) (A) and in prediagnostic sera samples (n = 26) relative to matched controls (n = 26) (prediagnostic set)
(C). Data are log2-transformed, and the average of control samples is set to 1.0. Mean ± standard error (SE) for controls and subjects with NSCLC are shown.
Receiver operating characteristic (ROC) curves for each ELISA assay and combined panel were analyzed in the newly diagnosed set (B) and in prediagnostic set
(D). ROC curves for a previously validated panel of autoantibodies to ANXA1, YWHAQ, and LAMR1 (Qiu et al., 2008) alone and in combination with the ELISA
panel are also shown (D).
(E) Levels of ROBO1 in plasmas from subjects with newly diagnosed SCLC (n = 10) relative to control subjects without cancer (n = 39). Data are log2-transformed,
and the average of control samples is set to 1.0. Boxes indicate 25th and 75th percentiles, and horizontal lines inside the boxes indicate median. Bars indicate 10th
and 90th percentiles, and black circles indicate data outside the 10th and 90th percentiles.
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Lung Cancer Protein Signatures in Mouse Plasmahuman counterparts. However, the use of such models to iden-
tify blood-based cancer signatures has been limited, and most
published studies have focused on single models (Faca et al.,
2008; Pitteri et al., 2011). The present study compared plasma
proteomes of a relatively large number of mouse models on
the basis of quantitative mass spectrometry. Analysis of the
plasma proteome profiles resulted in a clustering of the four
lung tumor models together, separate from other tumor models.
Among 39 proteins present at increased levels in plasmas296 Cancer Cell 20, 289–299, September 13, 2011 ª2011 Elsevier Infrom mice with lung adenocarcinoma (Table S5), 17 were extra-
cellular proteins, seven were localized to the plasma membrane,
and 11 were intracellular, as determined by Ingenuity Pathway
analysis. Furthermore, 21 of the proteins were demonstrated to
be enriched in conditioned media of lung adenocarcinoma cell
lines.
Of note, some previously described protein associations with
lung cancer (e.g., CEA, CYFRA21-1, and serum amyloid A) were
not revealed in our proteomic analysis of plasmas from lungc.
Cancer Cell
Lung Cancer Protein Signatures in Mouse Plasmaadenocarcinoma mouse models. CEA (Ceacam5) was neither
quantified nor identified in any mouse models, and CYFRA21-1
(fragment of Krt19) was only identified in the acute inflammation
model. On the other hand, CEACAM5 and KRT19 were identified
in 13 and 16 of 21 human lung adenocarcinoma cell lines,
respectively (data not shown). These discrepancies may be
due to the limitations of assay sensitivity of mass spectrometry
or the lack of significant elevations of these proteins at early
stages of tumor development (Van’t Westeinde and van Klave-
ren, 2011). Serum amyloid A (Saa1) was identified in all mouse
models used in this study, but was not quantified (Tables S2
and S3), because none of the identified Saa1 peptides contained
cysteine (data not shown). Therefore, Saa1 still could be a poten-
tial biomarker of lung cancer.
Strong evidence was obtained for a Titf1/Nkx2-1-related
signature in plasmas from mice with lung adenocarcinomas.
The evidence included expression of Titf1/Nkx2-1 and several
of its targets in mouse lung tumors, a positive correlation
between mRNA levels of protein signature genes and TITF1/
NKX2-1 expression in human lung cancers and cell lines, and
reduced expression of protein signature genes following knock-
down of TITF1/NKX2-1 with short inhibitory RNA. The finding
that a master regulator specific to a tissue lineage during airway
development, as in the case of TITF1/NKX2-1, regulates produc-
tion of proteins that are released into circulation with tumor
development provides a new avenue to search for cancer protein
signatures in plasma based on protein products of genes under
the control of master developmental regulators that are also
expressed during tumor development.
The discovery of an Egfr network in plasma from the mutant
EGFR lung cancer model with the highest statistical significance
among networks observed in that model suggests the occur-
rence in plasma of proteins that inform about genes and path-
ways driving tumor development. The Egfr signature included
Adam10, which is known to be induced by Egfr signaling
(McCulloch et al., 2004; Yan et al., 2002). Interestingly, Cdh1
and Cd44, which were also part of the Egfr containing network,
are substrates of Adam10 (Maretzky et al., 2005; Murai et al.,
2004). CD44 isoforms have been reported to occur in cancer
cells (Ponta et al., 2003). Although inclusion of variant exons is
stimulated by both RAS/MAPK pathway and EGF signaling
(Huot et al., 2009; Weg-Remers et al., 2001), alternatively spliced
isoforms of CD44 were found to occur predominantly in EGFR
mutant lung adenocarcinoma cell lines concordant with our
proteomic finding of peptides encoding Cd44 variant exon
sequences only in the EGFR mutant mouse model (Figure 3D).
Alternative splicing of CD44 has been linked to epithelial-mesen-
chymal transition triggers (Warzecha et al., 2009). Our CD44
peptide findings in the EGFR mutant mouse model and EGFR
mutant lung adenocarcinoma cell lines may be related to an
epithelial phenotype (Deng et al., 2009).
In our study, we observed distinct plasma protein signatures in
SCLC compared to NSCLC. They included proteins that re-
flected a neural lineage consistent with neuroendocrine features
of SCLC. Mouse Robo1 was the neural protein most elevated in
plasma from the SCLC mouse model compared to control mice.
Robo1 is a highly conserved axon guidance receptor and a
member of the NCAM family. Targeted deletion of the Robo1
gene affects lung development and results in bronchial hyper-Canplasia (Xian et al., 2001), and Slit-Robo1 signaling induces angio-
genesis (Wang et al., 2003). Assay of ROBO1 plasma levels in
human SCLC cases yielded concordant findings with the mouse
model with statistically significantly increased levels in cases
compared to healthy controls.
We obtained further evidence for concordance between find-
ings in lung cancer mouse models plasmas and human blood
samples with observations of reduced levels of circulating
EGFR in our study and in a prior study (Lemos-Gonza´lez et al.,
2007) and increased levels of circulating SFTPB, WFDC2, and
ANGPTL3 in our study. Of particular relevance to lung cancer
detection are results of assays using prediagnostic sera, which
also yielded concordant results indicative of a potential utility
of findings from mouse models for blood-based early detection
strategies of lung cancer and for monitoring of subjects with
the disease for tumor status.
EXPERIMENTAL PROCEDURES
Mouse Models and Mass Spectrometry Analysis for Mouse
Plasma Samples
All animal experiments were conducted in accordance with institutional and
national guidelines and regulations, under approval by the IACUC at Fred
Hutchinson Cancer Research Center. Plasma samples from mouse models
were obtained from tumor-bearing mice and control littermates. For each
mouse model, an independent pool of case and control plasma was created.
Pools of case and control plasma were formed by combining aliquots of
plasma from 4–10 mice (Table S1). Details on mouse models, plasma sample
preparation, mass spectrometry analysis, and statistical analysis are provided
in Supplemental Experimental Procedures.
Cell Lines
Twenty-one lung adenocarcinoma cell lines were profiled (Table S5). Detailed
analysis procedures and methods for cell culture, collection of whole cell
extracts, conditioned media and cell surface proteins, and mass spectrometry
analysis are given in Supplemental Experimental Procedures.
Informatic Analysis
For unsupervised hierarchical clustering of mouse plasma protein profile, the
Cluster program (http://rana.lbl.gov/EisenSoftware.htm) was used to perform
complete linkage hierarchical clustering of plasma proteins with filtering at
least 40% presence and log2 transformation, and the result was displayed
with the aid of TreeView software (http://rana.lbl.gov/EisenSoftware.htm)
(Eisen et al., 1998).
For pathway analysis, Ingenuity Pathway Analysis (IPA) Software (Ingenuity
Systems, Mountain View, CA) was used to perform pathway analysis of
elevated/decreased and uniquely identified proteins from plasma of geneti-
cally engineered lung mouse models.
Histology and Immunohistochemistory
Tissues were fixed in 4% paraformaldehyde overnight at room temperature,
placed in 70% ethanol, and sent for paraffin embedding and sectioning (Histo-
serv). The primary antibodies used for immunohistochemistry were anti-NPC2
(used at a dilution of 1:500, Sigma Cat. No. HPA000835), anti-surfactant
protein B (used at a 1:250 dilution; Abcam Cat. No. ab40876), and anti-thyroid
transcription factor 1 (used at a dilution of 1:200; Dako Cat. No. M3575).
Gene Expression and Western Blot Analysis
Microarray data for TITF1/NKX2-1 knockdown experiments was generated
with the Illumina Human HT-12 array platform. Details are found in Supple-
mental Experimental Procedures.
Human Plasma Samples
Plasma samples were obtained at the time of diagnosis from subjects with
operable NSCLC (n = 28), subjects with SCLC (n = 10), and healthy controlcer Cell 20, 289–299, September 13, 2011 ª2011 Elsevier Inc. 297
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Lung Cancer Protein Signatures in Mouse Plasmasubjects (n = 39) matched for age (±5 years), sex, and smoking history and
plasma collection protocol. Twenty-six pairs of prediagnostic NSCLC sera
samples and matched controls were collected 0–11 months prior to diagnosis
as part of theCarotene and Retinol Efficacy Trial (CARET) at the timewhen they
were completely asymptomatic. Control subjects were matched for age, sex,
and smoking history and were not diagnosed with cancer over a 4-year follow-
up period, irrespective of their state of general health otherwise. All human
plasma samples were obtained with the informed consent and the approval
of IRB at Fred Hutchinson Cancer Research Center.
ELISA Assays and Statistical Analysis
Levels of circulating EGFR (R& D Systems, dilution 1:300), SFTPB (USCN life,
dilution 1:2000), WFDC2 (IBL-America, dilution 1:10), and ANGPTL3 (IBL-
America, dilution 1:50) were measured according to the manufacturer’s proto-
cols. The resulting data were normalized according to the mean of control
subjects in each assay, and p values were calculated by use of the t test
and Mann-Whitney test. To avoid biasing issues in ROC analysis, panels
were generated using a linear combination of all assayed proteins. The level
of ROBO1 was determined by in-house sandwich ELISA for ectodomain of
ROBO1. Details on the ROBO1 ELISA assay are provided in Supplemental
Experimental Procedures.
ACCESSION NUMBERS
Microarray data sets were deposited in the National Center for Biotechnology
Information’s Gene Expression Omnibus (GEO) database (http://www.ncbi.
nlm.nih.gov/geo) with the accession number GSE28480.
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